The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma

Conclusions In the general study population, no improvement in lung function was observed with QAW039. However, a subgroup analysis revealed that patients with greater severity of airflow limitation (FEV1 < 70%) had improved lung function and asthma control when treated with QAW039. QAW039 also demonstrated a favorable safety profile. Trials registration ClinicalTrials.gov NCT01253603.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research